Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report
Keywords:chilblains, COVID-19, SARS-CoV-2 spike protein, COVID-19 mRNA vaccine, IFN
Abstract is missing (Short communication)
Matar S, Oulès B, Sohier P, Chosidow O, Beylot-Barry M, Dupin N, et al. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatology Venereol 2020; 34: e686-e689.
Le Cleach L, Dousset L, Assier H, Fourati S, Barbarot S, Boulard C, et al. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing*. Br J Dermatol 2020; 183: 866-874.
Aschoff R, Zimmermann N, Beissert S, Günther C. Type I interferon signature in chilblain-like lesions associated with the COVID-19 pandemic. Dermatopathology 2020; 7: 57-63.
Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol 2021; 157: 202-206.
Sohier P, Matar S, Meritet J-F, Laurent-Roussel S, Dupin N, Aractingi S. Histopathologic features of chilblainlike lesions developing in the setting of the coronavirus disease 2019 (COVID-19) pandemic. Arch Pathol Lab Med 2021; 145: 137-144.
McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46-55.
How to Cite
Copyright (c) 2021 Karim Souaid, Bénédicte Oulès, Pierre Sohier, Lydia Deschamps, Sélim Aractingi, Nicolas Dupin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.